Type-level market taxonomy separates copper peptides by their biochemical conjugation, directly influencing stability, cost structure and, ultimately, addressable market size. Pure Copper Peptide (GHK-Cu) remains the benchmark: high dermal bioavailability and 30-year INCI history justify its 55 % share of formulation volume, yet downstream players face escalating raw-material prices (+9 % YoY) as Chinese biotech suppliers consolidate. Copper Peptide Derivatives—liposomal, encapsulated or palmitoyl-coupled—command 2-4× the price per active gram and are growing 18 % CAGR; their value proposition is pH-independent stability, enabling inclusion in “clean” anhydrous balms and colour-cosmetic hybrids that broaden the channel footprint into Sephora-type prestige. Finally, Combination Formulations (GHK-Cu + retinoids, antioxidants, peptides) already represent one-third of new product launches; although they dilute the copper peptide story, they expand the treatable age-group from 45+ to 30+ and, by doing so, enlarge the category’s TAM by an estimated US $280 million in 2024.